Nitz, U., Gluz, O., Kreipe, H. H., Christgen, M., Kuemmel, S., Baehner, F. L., . . . Harbeck, N. (2020). The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer. Ther Adv Med Oncol.
Chicago Style citaatNitz, Ulrike, et al. "The Run-in Phase of the Prospective WSG-ADAPT HR+/HER2– Trial Demonstrates the Feasibility of a Study Design Combining Static and Dynamic Biomarker Assessments for Individualized Therapy in Early Breast Cancer." Ther Adv Med Oncol 2020.
MLA citatieNitz, Ulrike, et al. "The Run-in Phase of the Prospective WSG-ADAPT HR+/HER2– Trial Demonstrates the Feasibility of a Study Design Combining Static and Dynamic Biomarker Assessments for Individualized Therapy in Early Breast Cancer." Ther Adv Med Oncol 2020.